

P-194 - IN SILICO SELECTION OF AN SSDNA APTAMER AGAINST HER2-POSITIVE BREAST CANCER CELLS USING COMPUTATIONAL DOCKING SIMULATION

Diana Sousa¹; Débora Ferreira¹; Ligia Rodrigues¹

1 - Centre of Biological Engineering, University of Minho

Background

Human epidermal growth factor receptor type 2 (HER2/ErbB2) is a breast cancer associated protein overexpressed in 20% of breast cancers, being involved in cell growth regulation, survival and differentiation.^{1,2} The location of HER2 on the cell surface has contributed to its appeal as a tumour-targeted therapy.³ Aptamers, generated from Systematic Evolution of Ligands by EXponential Enrichment (SELEX), emerged as potential tool for application in target cancer therapy due to their three-dimensional structures that recognize cell surface receptors.⁴

Method

In this study, HER2-aptamers were screened and identified using SELEX technology. After cloning and sequencing, aptamers were modelled through m-fold software and posteriorly, the docking simulation was predicted using ZDOCK server.^{5,6} These *in silico* predictions measured the aptamer-HER2 interactions through a combination of shape complementarity and statistical potential terms for scoring.

Results & Conclusions

Based on *the interaction score*, a candidate ssDNA-aptamer (HER2-31; 5'-CACGTGCAGGGTGGATAGCAATCTATCCGGTCCCCTGTTCCGGTGGTCCG -3') was selected. Targeted-specificity of the selected HER2-31 was validated through cytometry and fluorescence microscopy assays in HER2-positive breast cancer cells. Our results indicate that SELEX technology is an efficient method to screen specific protein-bound ssDNA, and HER2-31 could be used as an agent in HER2-based diagnosis and targeted therapy. Also, the results provide valuable guidelines for the application of docking simulations for the prediction of aptamer-ligand structures, as well as for the design of novel features of ligand-aptamer complexes.

References & Acknowledgments

1. Iqbal, N. & Iqbal, N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. *Mol. Biol. Int.* **2014**, 852748 (2014).
2. Mendes, D. *et al.* The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer - a systematic review. *Breast Cancer Res.* **17**, 140 (2015).
3. English, D. P., Roque, D. M. & Santin, A. D. HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies. *Mol. Diagn. Ther.* **17**, 85–99 (2013).
4. Dupont, D. M., Larsen, N., Jensen, J. K., Andreasen, P. A. & Kjems, J. Characterisation of aptamer-target interactions by branched selection and high-throughput sequencing of SELEX pools. *Nucleic Acids Res.* **43**, e139 (2015).
5. Catherine, A. T., Shishido, S. N., Robbins-Welty, G. A. & Diegelman-Parente, A. Rational design of a structure-switching DNA aptamer for potassium ions. *FEBS Open Bio* **4**, 788–95 (2014).
6. Pierce, B. G. *et al.* ZDOCK server: interactive docking prediction of protein–protein complexes and symmetric multimers. 1–3 (2014). doi:10.1093/bioinformatics/btu097

In silico selection of an ssDNA aptamer against HER2-positive breast cancer cells using computational docking simulation

Keywords: aptamers, SELEX, breast cancer, HER 2